Preferencje help
Polish version English version Język
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 22

Liczba wyników na stronie
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników

Wyniki wyszukiwania

help Sortuj według:

help Ogranicz wyniki do:
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
1

Analiza mozliwosci zmniejszenia strat ciepla w szklarniach na terenie Polski poludniowej

100%
Cichon T.
Zeszyty Naukowe Akademii Rolniczej w Krakowie. Sesja Naukowa
|
1997
|
tom 49
17-27
2
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Efforts to reduce water losses in large water companies

63%
Cichon T., Krolikowska J.
Ekonomia i Środowisko
|
2017
|
nr 1[60]
3

Combination of combretastatin A4 phosphate and doxorubicin-containing liposomes affetcs growth of B16-F10 tumors

51%
Mitrus I., Sochanik A., Cichon T., Szala S.
Acta Biochimica Polonica
|
2009
|
tom 56
|
nr 1
161-165
The study aimed to check the effectiveness of anticancer therapy combining a vascular-disruptive drug (combretastatin phosphate, CA4P) and a liposomal formulation of a chemotherapeutic (doxorubicin). CA4P was synthesized in our laboratory according to a previously described procedure. The antivascular drug and long-circulating doxorubicin-loaded liposomes were used to treat B16-F10 murine melanoma experimental tumors. Seventy-four hours after drug administration, a decrease in the number of tumor blood vessels was apparent and necrotic areas within tumors were visible. Combination therapy consisting of alternate administrations of CA4P and liposomal doxorubicin yielded greater inhibition of tumor growth than monotherapies alone. The best therapeutic results were obtained with the antivascular drug administered intratumorally every second day at 50 mg/kg body mass. In the case of combined therapy, the best results were obtained when the vascular-disruptive agent (CA4P) and the antineoplastic agent (liposomal doxorubicin) were administered in alternation.
4

Antiangiogenic therapy of B16(F10) melanoma metastases in mouse lungs

51%
Cichon T., Sochanik A., Szala S.
Acta Biochimica Polonica
|
2003
|
tom 50
|
nr Supplement 1
5

Charakterystyczne wskaźniki techniczne i użytkowe budownictwa inwentarskiego na Spiszu

51%
Bieda W., Cichon T., Nowakowski N., Radon J.
Zeszyty Naukowe Akademii Rolniczej w Krakowie. Sesja Naukowa
|
1990
|
tom 25
6

Use of conjugate of paclitaxel with PGA in melanoma tumour therapy in mice

51%
Mitrus I., Cichon T., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
7

Antiangiogenic gene therapy in inhibition of metastasis

51%
Szala S., Szary J., Cichon T., Sochanik A.
Acta Biochimica Polonica
|
2002
|
tom 49
|
nr 2
This short review attempts to demonstrate the usefulness of antiangiogenic gene therapy in achieving inhibition of growth in experimentally-induced metastases. Cer­tain normal tissues (for example skeletal muscle) may be used in vivo, after genetic modification, as a "bioreactor", able to produce and secrete into the bloodstream pro­teins known to exert antiangiogenic effects. By inhibiting neoangiogenesis these pro­teins would thus prevent the development of metastases. The review discusses also the perspectives of antimetastatic therapy based on certain types of allogenic cells (for example myoblasts and fibroblasts) that had been genetically modified and then microencapsulated. The strategy of encapsulation is aimed at protecting the modified cells secreting antiangiogenic factors from being eliminated by the immune system. Secretion of antiangiogenic proteins by these microencapsulated cells can be con­trolled with inducible promoters. Antiangiogenic genes remaining under the transcriptional control of such promoters may be switched on and off using antibiot­ics, such as tetracycline derivatives, or steroid hormones.
8

Direct in vivo transfer of plasmid DNA into murine tumors: Effects of endotoxin presence and transgene localization

51%
Budryk M., Cichon T., Szala S.
Acta Biochimica Polonica
|
2001
|
tom 48
|
nr 3
The purpose of this study was to investigate the effect of endotoxin presence in plasmid DNA preparations on the efficiency of transfection achieved in vivo with B16(F10) and Renca tumors and to determine transgene localization. Our data show that endotoxin markedly decreases the efficiency of transfection. Furthermore, the transgene transferred in vivo can be found in both neoplastic and normal (most likely myofibroblast) cells lying in proximity of the administration site.
9
Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik
Content available

Accuracy of water meters during their operation

51%
Cichon T., Krolikowska J.
Ekonomia i Środowisko
|
2018
|
nr 2[65]
10

Combination of anticancer peptide (CAMEL) with immunotherapy in B16(F10) murine melanoma tumor therapy

45%
Smolarczyk R., Cichon T., Kamysz W., Nadolny R., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
11

Chimeric protein ABRaA-VEGF121 is cytotoxic towards VEGFR-2-expressing PAE cells and inhibits B16-F10 melanoma growth

45%
Smagur A., Boyko M. M., Biront N. V., Cichon T., Szala S.
Acta Biochimica Polonica
|
2009
|
tom 56
|
nr 1
115-124
It has been known that VEGF121 isoform can serve as a carrier of therapeutic agents targeting tumor endothelial cells. We designed and constructed synthetic cDNA that encodes a chimeric protein comprising abrin-a (ABRaA) toxin A-chain and human VEGF121. Expression of the ABRaA-VEGF121 chimeric protein was carried out in E. coli strain BL21(DE3). ABRaA-VEGF121 preparations were isolated from inclusion bodies, solubilized and purified by affinity and ion-exchanged chromatography (Ni-agarose and Q-Sepharose). Finaly, bacterial endotoxin was removed from the recombinant protein. Under non-reducing conditions, the recombinant protein migrates in polyacrylamide gel as two bands (about 84 kDa homodimer and about 42 kDa monomer). ABRaA-VEGF121 is strongly cytotoxic towards PAE cells expressing VEGFR-2, as opposed to VEGFR-1 expressing or parental PAE cells. The latter are about 400 times less sensitive to the action of this fusion protein. The biological activity of the ABRaA domain forming part of the chimeric protein was assessed in vitro: ABRaA-VEGF121 inhibited protein biosynthesis in a cell-free translation system. Preincubation of ABRaA-VEGF121 with antibody neutralizing the biological activity of human VEGF abolished the cytotoxic effect of the chimeric protein in PAE/KDR cells. Experiments in vivo demonstrated that ABRaA-VEGF121 inhibits growth of B16-F10 murine melanoma tumors.
12

Combined anticancer therapy using antivascular peptide and folate-targeted liposomes carrying doxorubicin

45%
Sochanik A. S., Smolarczyk R., Mitrus I., Cichon T., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
13

New chimeric protein ABRaA-VEGF121 is selectively cytotoxic towards cells overexpressing VEGFR2 (KDR) and inhibits growth of primary tumors

45%
Smagur A., Boyko M., Biront N., Cichon T., Szala S.
Acta Biochimica Polonica
|
2007
|
tom 54
|
nr Supplement 4
14

D-K6L9 peptide combination with IL-12 inhibits the recurrence of tumors in mice

39%
Cichon T., Smolarczyk R., Matuszczak S., Barczyk M., Jarosz M., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2014
|
tom 62
|
nr 4
15

Combined tumor cell-based vaccination and interleukin-12 gene therapy polarizes the tumor microenvironment in mice

39%
Jarosz-Biej M., Smolarczyk R., Cichon T., Kulach N., Czapla J., Matuszczak S., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2015
|
tom 63
|
nr 6
16

Properties of B16-F10 murine melanoma cells subjected to metabolic stress conditions

39%
Mitrus I., Bryndza E., Kazura M., Smagur A., Sochanik A., Cichon T., Szala S.
Acta Biochimica Polonica
|
2012
|
tom 59
|
nr 3
Neoplastic cells which co-form tumors are usually subjected to various stress factors, mainly hypoxia and shortage of nutrient factors. Such cells employ different strategies that permit their survival under such conditions. Experiments in vitro are usually carried out in the presence of 21% oxygen and medium supplemented with 10% FBS. Altering these parameters can approximate the in vivo conditions found within tumor mass. The present paper reports certain properties (especially ability to metastasize) of B16-F10 cells able to grow upon exposure to altered growth conditions (medium supplemented with 0.06% FBS or presence of 1% oxygen for 24 or 72 hours). These properties were compared with those of control cells cultured in the presence of 21% oxygen and in medium supplemented with 10% FBS. Some properties of the cells exposed to medium supplemented with 0.06% FBS differ from those of cells cultured under low oxygenation conditions (ability to form metastases, to migrate, or to express various proteins). Only the partial deprivation of oxygen did increase both the number of migrating cells and the number of metastases formed. Serum deficiency enhanced only the cell ability to metastasize, but not to migrate. It appears that cultured B16-F10 cells employ different adaptation strategies under conditions of oxygen shortage and those of serum deficiency. Under oxygen deprivation, such cells most likely undergo an epithelial-mesenchymal transition, whereas serum deficiency ("starvation"), while increasing the tumorigenicity of B16-F10 cells, does not induce the epithelial-mesenchymal transition.
17

Experimental anticancer therapy with vascular-disruptive peptide and liposome-entrapped chemotherapeutic agent

39%
Sochanik A., Mitrus I., Smolarczyk R., Cichon T., Snietura M., Czaja M., Szala S.
Archivum Immunologiae et Therapiae Experimentalis
|
2010
|
tom 58
|
nr 3
235-245
18

Antitumor effect of RGD-4C-CG-D(KLAKLAK)2 peptide in mouse B16(F10) melanoma model

39%
Smolarczyk R., Cichon T., Graja K., Hucz J., Sochanik A., Szala S.
Acta Biochimica Polonica
|
2006
|
tom 53
|
nr 4
19

In vivo gene transfer using cetylated polyethylenimine

39%
Sochanik A., Cichon T., Makselon M., Strozyk M., Smolarczyk R., Jazowiecka-Rakus J., Szala S.
Acta Biochimica Polonica
|
2004
|
tom 51
|
nr 3
This report describes gene transfer in vitro as well as in vivo using cetylated low-molecular mass (600 Da) polyethylenimine (28% of amine groups substituted with cetyl moieties), termed CT-PEI. This compound is hydrophobic and has to be in­corporated into liposomes in order to be suitable for gene transfer studies. Serum-in­duced plasmid DNA degradation assay demonstrated that CT-PEI-containing lipo­somal carriers could protect complexed DNA (probably via condensation). In vitro lu- ciferase gene expression achieved using medium supplemented with 10% serum was comparable to that achieved in serum-reduced medium and was highest for CT-PEI/cholesterol liposomes, followed by CT-PEI/dioleoylphosphatidylcholine liposomes and PEI 600 Da (uncetylated) carrier. In vivo systemic transfer into mice was most efficient when liposome formulations contained CT-PEI and cholesterol. Higher luciferase expression was then observed in lungs than in liver. In conclusion: liposomes containing cetylated polyethylenimine and cholesterol are a suitable vehicle for investigating systemic plasmid DNA transfer into lungs.
20

Vasostatin increases oxygenation of B16-F10 melanoma tumors and raises therapeutic efficacy of cyclophosphamide

33%
Cichon T., Jarosz M., Smolarczyk R., Ogorek B., Matuszczak S., Wagner M., Mitrus I., Sochanik A., Jazowiecka-Rakus J., Szala S.
Acta Biochimica Polonica
|
2012
|
tom 59
|
nr 3
One of the preconditions of effective anticancer therapy is efficient transfer of the therapeutic agent (chemotherapeutic) to tumor cells. Fundamental barriers making drug delivery and action difficult include underoxygenation, elevated interstitial pressure, poor and abnormal tumor blood vascular network and acidic tumor milieu. In this study we aimed at developing an optimized scheme of administering a combination of an angiogenesis-inhibiting drug (vasostatin) and a chemotherapeutic (cyclophosphamide) in the therapeutic treatment of mice bearing experimental B16-F10 melanoma tumors. We report that the strongest tumor growth inhibition was observed in mice that received two, three or four vasostatin doses in combination with one injection of cyclophosphamide (i.e., V2 + CTX, V3 + CTX or V4 + CTX schemes). Double administration of vasostatin increases oxygenation of B16-F10 tumors. On the other hand, its five-fold administration lowers tumor oxygenation, breaks down tumor vascular network (increasing hypoxia) and leads in consequence to death of cancer cells and appearance of necrotic areas in the tumor. A decreased cyclophosphamide dose in combination with two doses of vasostatin (V2 + CTX scheme) inhibits tumor growth similarly to a larger dose of cyclophosphamide alone.
Pierwsza strona wyników Pięć stron wyników wstecz Poprzednia strona wyników Strona / 2 Następna strona wyników Pięć stron wyników wprzód Ostatnia strona wyników
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.